| Symbol | AIM |
|---|---|
| Name | AIM IMMUNOTECH INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 2117 SW HIGHWAY 484, OCALA, FL 32801 |
| Telephone | 352-448-7797 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000946644 |
| Description | None |
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
Read moreAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
Read moreAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
Read moreAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
Read more(90% Positive) AIM IMMUNOTECH INC. (AIM) Announces Enrollment Update for results Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
Read moreAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
Read moreAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
Read more